Distributors of mifepristone, an FDA-approved drug to induce an abortion, may continue shipping the medication for at least one week, according to a May 4 order from the Supreme Court.
The order temporarily stays a May 1 decision from the 5th Circuit Court of Appeals, which ruled against an FDA decision that granted mail-order pharmacies to ship mifepristone. The agency approved the allowance in 2021 and enacted it in 2023.
Approved in 2000, mifepristone is indicated to terminate a pregnancy within the first 10 weeks of gestation. A Louisiana lawsuit filed in September seeks to retract the mail-order allowance for mifepristone. An appeals court ruled the FDA’s removal of the in-person dispensing requirement was “likely unlawful,” claiming it was based on inadequate data, has injured women and fetuses, and has obstructed Louisiana’s near-total abortion ban.
Danco Laboratories and GenBioPro, two manufacturers and distributors of mifepristone, appealed the matter to the Supreme Court.
As the Supreme Court considers the case, the stay will last until the evening of May 11.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
